Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1962 | Maltodextrin Wiki | 1.00 |
| drug1493 | Home Sleep Apnea Testing or In-hospital Polysomnography Wiki | 1.00 |
| drug537 | Bovine Lactoferrin Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D001049 | Apnea NIH | 1.00 |
| D020181 | Sleep Apnea, Obstructive NIH | 0.58 |
| D012891 | Sleep Apnea, NIH | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002870 | Obstructive sleep apnea HPO | 0.58 |
| HP:0010535 | Sleep apnea HPO | 0.50 |
| HP:0002090 | Pneumonia HPO | 0.06 |
Navigate: Correlations HPO
There is one clinical trial.
Covid-19 infection is an on-going pandemic with worse diagnosis in adults with comorbid conditions such as hypertension and cardiopulmonary diseases. Obstructive sleep apnea (OSA) is common in those comorbidities and may contribute to worse prognosis for the Covid-19 cases.
Description: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 7 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 14 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 21 daysDescription: Defined as a decline of 2 categories from admission on a 7-category ordinal scale
Measure: The rate of clinical improvement Time: 28 daysDescription: Time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality
Measure: Clinical status - improvement Time: 7, 14, 21, 28 daysDescription: Defined as an increase in category on a 7-category ordinal scale from admission
Measure: Clinical status - worsening Time: 7, 14, 21, 28 daysDescription: Re-analysis of the correlation of obstructive sleep apnea (objectively verified) severity in terms of apnea-hypopnea index and oxygenation levels with the primary and secondary outcomes as described above (the rate of clinical improvement defined as a decline of 2 categories from admission on a 7-category ordinal scale; time to hospital discharge, ICU discharge, weaning from intubation, weaning from supplemental oxygen, incident pneumonia, ARDS, in-hospital mortality as well as with the lung function, CO-diffusion capacity, cardiac function, CT thorax pathologies, biomarkers (cytokines, polymorphisms) and IgG-antibodies after 4 months.
Measure: Long-term outcomes Time: 4-6 months after the initial hospital admissionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports